The Alliance Submits Comments to the CDC and ACIP on the FDA Authorized Novovax COVID-19 Vaccine
Published July 19, 2022
The Alliance for Aging Research submitted comments to the Center for Disease Control and Prevention’s Advisory Committee on Immunization (ACIP) regarding access to the newly Food and Drug Administration (FDA) authorized Novavax COVID-19 vaccine for individuals aged 18 and above. In the comments, the Alliance thanked ACIP for unanimously recommending the new vaccine; thereby ensuring that older adults have access to the new preventative should they want it. Due to the increased risk of severe COVID-19 illness in older adults there has been a push to ensure that the entire population of those aged 65 and older are vaccinated. There is potential that additional vaccine options, especially those that are perceived as having been developed in a more “traditional” fashion such as the Novavax vaccine, will appeal to individuals that remain COVID-19 vaccine hesitant. Patients and clinicians need access to a broad spectrum of prevention and treatment tools as the virus continues to evolve and become endemic. As such, it is essential that patients are able to access all vaccines that are authorized or approved by the FDA. Yesterday’s decision will function to help ensure that access is realized.
Read the full comment letter HERE.